Ctrl K
Wall Street consensus, price target range, and equity research thesis
Wall Street currently rates NVS hold with a 12-month price target of $170 (+11.9% upside). The sections below cover the bull case, key risks, and latest earnings context for Novartis AG.
Analyst ratings update weekly. Get NVS's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
Analyst Research Summary
A structured look at the bull case, the risks, and the most recent earnings execution for NVS.
NVS beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
What keeps the long thesis intact
Wall Street rates NVS hold, giving the bull case institutional backing from 25 analysts.
What can break the setup quickly
Watch whether new negative commentary on NVS points to these structural risks or is simply reacting to short-term price moves.
Last Quarter
Stock snapshot, live price chart, key ratios, and company profile.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NVS stock.
NVS has modest upside — analysts rate it "Hold" with a $170 target, implying +11.9% from today's $151.97. This is informational only — verify the data and consider your own risk tolerance before deciding.
Timing depends on your horizon, but the data signals are: consensus rating "Hold" with +11.9% upside to the $170 target.
NVS's consensus 12-month price target is $170, set by 25 Wall Street analysts. The bull case high is $170 and the bear case low is $170. From the current price of $151.97, this implies +11.9% upside.
NVS appears fairly valued — the $170 consensus target is roughly in line with today's $151.97 (+11.9%). It trades at a forward P/E of 17.3x. Targets range from $170 (bear) to $170 (bull), reflecting different assumptions about growth and margins.
NVS reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Hold" with a $170 target. Consider position sizing rather than going all-in pre-print.
Of 25 analysts covering Novartis AG (NVS): 0 Strong Buy, 6 Buy, 17 Hold, 2 Sell, 0 Strong Sell — a "Hold" consensus. The 12-month price target is $170 (range $170–$170). Bullish analysts outnumber bearish by more than 2-to-1.
2 of the 25 analysts covering NVS rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Novartis AG.
Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Consensus ratings and price targets reflect aggregated third-party Wall Street analyst research from public SEC filings. See our Terms of Service and Privacy Policy.